Biological barriers cause major limitations to the treatment for many diseases. Improving the transport of drugs across these biological barriers, without compromising the defence capability, is a critical issue in the treatment of diseases. These barriers are naturally built to be selective, preventing unwanted foreign molecules from entry while enabling useful molecules to pass through a transcytosis process.
Biological barriers that prevent drug transport inhibit drug accumulation, specifically in disease areas, which limits the efficacy of many therapies. The solution to this problem is represented by receptor-specific nanocarriers capable of transporting diverse kinds of molecules through these barriers by specialized mechanisms.
Nanoparticles include drug particles, drug-carrier particles, and drug-carrier complexes in the size range of 10-1000 nm. Nanoparticles have unique therapeutic capabilities due to their small size, which are not present in the drugs themselves. Improved solubility, greater stability, improved permeability, reduced toxicity, and increased drug accumulation in the appropriate location are some of the desired distinctive features that nanoparticles exhibit. Nanoparticles-based targeted drug delivery enables drug delivery kinetics to be controlled and, more importantly, specific areas to be reached, decreasing adverse effects and undesirable high doses.
The goal of this Research Topic is to highlight the various approaches to improve drug permeability across biological barriers, such as intestinal mucosa, skin, blood brain barrier (BBB), nasal mucosa, lung surface and blood nerve barrier, etc. Articles including original research and review articles on the following themes, but not limited to these, are welcome to the collection:
- Functionalized nanoparticles
- Nanomedicine
- Nano-pharmaceuticals
- Organic nanoparticles
- Inorganic nanoparticles
Please note: Original research based solely on in silico techniques will not be considered for review.
Biological barriers cause major limitations to the treatment for many diseases. Improving the transport of drugs across these biological barriers, without compromising the defence capability, is a critical issue in the treatment of diseases. These barriers are naturally built to be selective, preventing unwanted foreign molecules from entry while enabling useful molecules to pass through a transcytosis process.
Biological barriers that prevent drug transport inhibit drug accumulation, specifically in disease areas, which limits the efficacy of many therapies. The solution to this problem is represented by receptor-specific nanocarriers capable of transporting diverse kinds of molecules through these barriers by specialized mechanisms.
Nanoparticles include drug particles, drug-carrier particles, and drug-carrier complexes in the size range of 10-1000 nm. Nanoparticles have unique therapeutic capabilities due to their small size, which are not present in the drugs themselves. Improved solubility, greater stability, improved permeability, reduced toxicity, and increased drug accumulation in the appropriate location are some of the desired distinctive features that nanoparticles exhibit. Nanoparticles-based targeted drug delivery enables drug delivery kinetics to be controlled and, more importantly, specific areas to be reached, decreasing adverse effects and undesirable high doses.
The goal of this Research Topic is to highlight the various approaches to improve drug permeability across biological barriers, such as intestinal mucosa, skin, blood brain barrier (BBB), nasal mucosa, lung surface and blood nerve barrier, etc. Articles including original research and review articles on the following themes, but not limited to these, are welcome to the collection:
- Functionalized nanoparticles
- Nanomedicine
- Nano-pharmaceuticals
- Organic nanoparticles
- Inorganic nanoparticles
Please note: Original research based solely on in silico techniques will not be considered for review.
